Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-08 | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca
(Pres., R&D, and CMO) |
S | Common Stock | D | 2676 | $243.25 - $248.58 | $658,255 |
| 2024-04-08 | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca
(Pres., R&D, and CMO) |
M | Common Stock | A | 2676 | $9.45 - $9.45 | $25,288 |
| 2024-04-08 | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A
(Director) |
S | Common Stock | D | 26270 | $242.95 - $248.59 | $6,467,487 |
| 2024-04-08 | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A
(Director) |
M | Common Stock | A | 26270 | $9.45 - $9.45 | $248,251 |
| 2024-04-03 | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca
(Pres., R&D, and CMO) |
S | Common Stock | D | 73888 | $240.11 - $248.23 | $18,022,578 |
| 2024-04-03 | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca
(Pres., R&D, and CMO) |
M | Common Stock | A | 73888 | $9.45 - $9.45 | $698,240 |
| 2024-04-03 | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A
(Director) |
S | Common Stock | D | 73730 | $240.10 - $248.43 | $17,984,794 |
| 2024-04-03 | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A
(Director) |
M | Common Stock | A | 73730 | $9.45 - $9.45 | $696,747 |
| 2024-04-01 | MADRIGAL PHARMACEUTICALS, INC. | Levy Richard S
(Director) |
S | Common Stock | D | 11000 | $255.90 - $267.07 | $2,832,331 |
| 2024-04-01 | MADRIGAL PHARMACEUTICALS, INC. | Levy Richard S
(Director) |
M | Common Stock | A | 11000 | $7.36 - $111.06 | $703,160 |
| 2024-04-01 | MADRIGAL PHARMACEUTICALS, INC. | BATE KENNETH
(Director) |
S | Common Stock | D | 32489 | $243.28 - $266.91 | $8,214,992 |
| 2024-04-01 | MADRIGAL PHARMACEUTICALS, INC. | BATE KENNETH
(Director) |
M | Common Stock | A | 32489 | $9.45 - $105.08 | $2,411,343 |
| 2024-04-01 | MADRIGAL PHARMACEUTICALS, INC. | Daly James M
(Director) |
S | Common Stock | D | 32489 | $243.26 - $266.91 | $8,218,623 |
| 2024-04-01 | MADRIGAL PHARMACEUTICALS, INC. | Daly James M
(Director) |
M | Common Stock | A | 32489 | $100.45 - $105.08 | $3,321,343 |
| 2024-01-23 | MADRIGAL PHARMACEUTICALS, INC. | Huntsman Carole
(Chief Commercial Officer) |
A | Common Stock | A | 3639 | $0.00 - $0.00 | $0 |
| 2024-01-23 | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca
(Pres., R&D, and CMO) |
A | Common Stock | A | 5786 | $0.00 - $0.00 | $0 |
| 2024-01-23 | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E.
(Senior VP, Chief Pharma Dev.) |
A | Common Stock | A | 1419 | $0.00 - $0.00 | $0 |
| 2024-01-23 | MADRIGAL PHARMACEUTICALS, INC. | Howarth Alex G.
(Chief Financial Officer) |
A | Common Stock | A | 4803 | $0.00 - $0.00 | $0 |
| 2024-01-23 | MADRIGAL PHARMACEUTICALS, INC. | Lynch Brian Joseph
(SVP and General Counsel) |
A | Common Stock | A | 3639 | $0.00 - $0.00 | $0 |
| 2024-01-23 | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John
(President and CEO) |
A | Common Stock | A | 12250 | $0.00 - $0.00 | $0 |
| 2024-01-16 | MADRIGAL PHARMACEUTICALS, INC. | Lynch Brian Joseph
(SVP and General Counsel) |
F | Common Stock | D | 949 | $243.92 - $243.92 | $231,480 |
| 2023-01-16 | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A
(Director) |
F | Common Stock | D | 2254 | $243.92 - $243.92 | $549,795 |
| 2024-01-16 | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca
(Pres., R&D, and CMO) |
F | Common Stock | D | 1546 | $243.92 - $243.92 | $377,100 |
| 2024-01-16 | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E.
(Senior VP, Chief Pharma Dev.) |
F | Common Stock | D | 550 | $243.92 - $243.92 | $134,156 |
| 2024-01-16 | MADRIGAL PHARMACEUTICALS, INC. | Howarth Alex G.
(Chief Financial Officer) |
F | Common Stock | D | 1067 | $243.92 - $243.92 | $260,262 |
| 2023-12-12 | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E.
(Senior VP, Chief Pharma Dev.) |
S | Common Stock | D | 3800 | $216.00 - $226.00 | $846,700 |
| 2023-12-13 | MADRIGAL PHARMACEUTICALS, INC. | Baker Brothers Li...
(Director) |
P | Common Stock | A | 101792 | $216.70 - $229.86 | $22,516,565 |
| 2023-12-12 | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E.
(Senior VP, Chief Pharma Dev.) |
M | Common Stock | A | 3800 | $87.92 - $87.92 | $334,096 |
| 2023-12-04 | MADRIGAL PHARMACEUTICALS, INC. | Lynch Brian Joseph
(SVP and General Counsel) |
S | Common Stock | D | 2800 | $215.73 - $227.33 | $621,294 |
| 2023-12-04 | MADRIGAL PHARMACEUTICALS, INC. | Lynch Brian Joseph
(SVP and General Counsel) |
M | Common Stock | A | 2800 | $73.75 - $87.09 | $233,180 |
| 2023-11-29 | MADRIGAL PHARMACEUTICALS, INC. | Lynch Brian Joseph
(SVP and General Counsel) |
S | Common Stock | D | 7000 | $198.40 - $206.73 | $1,410,480 |
| 2023-11-29 | MADRIGAL PHARMACEUTICALS, INC. | Lynch Brian Joseph
(SVP and General Counsel) |
M | Common Stock | A | 7000 | $73.75 - $73.75 | $516,250 |
| 2023-11-20 | MADRIGAL PHARMACEUTICALS, INC. | Huntsman Carole
(Chief Commercial Officer) |
A | Common Stock | A | 7834 | $0.00 - $0.00 | $0 |
| 2023-11-21 | MADRIGAL PHARMACEUTICALS, INC. | Baker Brothers Li...
(Director) |
P | Common Stock | A | 64350 | $183.16 - $190.14 | $12,128,332 |
| 2023-11-17 | MADRIGAL PHARMACEUTICALS, INC. | Baker Brothers Li...
(Director) |
P | Common Stock | A | 67079 | $167.63 - $189.70 | $11,947,263 |
| 2023-11-14 | MADRIGAL PHARMACEUTICALS, INC. | Baker Brothers Li...
(Director) |
P | Common Stock | A | 49387 | $156.42 - $161.97 | $7,809,557 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |